Dupilumab for children with prurigo nodularis
Treatments studied
Part of Skin clinical trials.
This study tests whether the medication dupilumab can safely reduce itching and skin bumps in children aged 6 months to under 18 years who have prurigo nodularis, a skin condition that causes intense itching and nodules. Participation involves taking the study drug and tracking itch daily.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 6 months and under 18 years old.
- You must have a diagnosis of prurigo nodularis for at least 3 months.
- You must have at least 6 itchy bumps (lesions) on at least 2 different parts of the body.
- Your itch score must be 7 or higher on a 0-10 scale (for older children) or similar for younger ones.
- Caregivers must be willing to complete a daily electronic diary about symptoms.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how well nemolizumab works in real-world settings for adults with moderate-to-severe prurigo nodularis, a skin condition that causes intense itching and bumps. If you are starting this medication as part of your normal care, you may be able to join.
This trial tests an injection called SHR-1819 for adults with prurigo nodularis, a skin condition with itchy bumps. The goal is to see if it helps reduce itching and bumps.
This trial tests an investigational drug called MG-K10 for people with prurigo nodularis, a skin condition that causes intense itching and bumps. The goal is to see if it can help reduce itch and improve skin.
This study follows people with moderate-to-severe prurigo nodularis who are starting dupilumab. It looks at how the medicine works over time and how it affects the immune system, to help understand long-term benefits.
This Phase 3 study tests whether dupilumab injections can reduce severe itching that has no clear cause. It also checks how safe the medicine is over the study period.
This trial tests an experimental drug called ICP-332 for people with prurigo nodularis (a condition causing very itchy, hard bumps on the skin). It aims to see if the drug can safely reduce itching and improve skin lesions.
Hear when a new Prurigo Nodularis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.